{"id":41060,"date":"2023-10-06T05:54:56","date_gmt":"2023-10-06T05:54:56","guid":{"rendered":"https:\/?p=41060"},"modified":"2023-10-06T05:54:56","modified_gmt":"2023-10-06T05:54:56","slug":"fold-stock-forecast-j-p-morgans-top-2-picks-for-the-year-ahead","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/fold-stock-forecast-j-p-morgans-top-2-picks-for-the-year-ahead\/","title":{"rendered":"FOLD Stock Forecast: J.P. Morgan’s Top 2 Picks for the Year Ahead"},"content":{"rendered":"

Investors are dealing with challenges ranging from Federal Reserve policies to geopolitical tensions and inflation concerns, J.P. Morgan’s global investment strategist, Madison Faller, offers a glimmer of hope. Despite the economic unrest, Faller suggests that stocks may scale new heights in the coming year. J.P. Morgan analysts recommend two equities for inclusion in your portfolio and Amicus Therapeutics (<\/span>FOLD:NSD<\/span><\/a>) and DigitalBridge Group (<\/span>DBRG:NYE<\/span><\/a>) stand out as promising additions. This article will highlight the DBRG and FOLD stock forecast.<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Amicus Therapeutics (FOLD)<\/span><\/h2>\n

Amicus Therapeutics, the firm boasts two approved drugs on the market, Galafold and the combination therapy Pombiliti and Opfolda. Moreover, These offerings have paved the way for a consistent revenue stream, with the company reporting $94.5 million in global revenue for 2Q23, surpassing expectations by approximately $4.6 million and marking a 17% YoY increase.<\/span><\/p>\n

 <\/p>\n

Promising Outlook for 2023<\/span><\/h3>\n

Looking ahead, Amicus anticipates robust growth, forecasting a 14% to 18% revenue increase for Galafold in 2023. This optimistic outlook is underpinned by strong demand and commercial expansion in key markets such as the US, UK, EU, and Japan. Furthermore, regulatory approval from the EU in Q2 for the commercial launch of the Pombiliti+Opfolda combination therapy adds to Amicus’ potential.<\/span><\/p>\n

 <\/p>\n

JPMorgan’s Positive Assessment:<\/span><\/h3>\n

JPMorgan<\/span><\/a>\u00a0analyst Anupam Rama is bullish on Amicus, highlighting that “solid execution on the Galafold and Pombiliti+Opfolda should drive value into the mid-to high-teens\/share level.” Rama rates FOLD as an “Overweight” (Buy) with a one-year target price of $19, suggesting an impressive 71% upside potential.\u00a0<\/span>Bank of America Merrill Lynch<\/span><\/a>\u00a0raised the target for FOLD stock from USD 16 to USD 19.<\/span><\/p>\n

 <\/p>\n

FOLD Stock Forecast:<\/span><\/h3>\n

Based on the FOLD stock forecast from two analysts, the average target price is USD 19.00 over the next 12 months. This sentiment aligns with the consensus rating of “Strong Buy.” At the last closing, the stock was trading at USD 10.78.<\/span><\/p>\n

<\/p>\n

\n
\n

FOLD Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n